By Ranjeet

RXDX Stock Forecast, Price & News

Image Credit : Unsplash

Formed in 1996, Prometheus Biosciences, Inc. is a biopharmaceutical firm dedicated to the research,

Image Credit : Unsplash

The development and commercialization of innovative medicines and companion diagnostics for the management of inflammatory bowel disease (IBD).

Image Credit : Unsplash

PRA023 is a humanised IgG1 monoclonal antibody that is the company's flagship product (mAb),

Image Credit : Unsplash

which is currently undergoing a Phase IIa clinical trial for the treatment of inflammatory bowel illness, chronic lung disease caused by systemic sclerosis, and Crohn's disease.

Image Credit : Unsplash

Furthermore, the firm is working on the following products for IBD: PR600 (an anti-tumor necrosis factor mAb), PR300 (a G-protein coupled receptor modulator small molecule), and PR1100 (an anti-tumor necrosis factor mAb).

Image Credit : Unsplash

PR2100 is an anti-inflammatory cytokine mAb for IBD, while PR1800 is an anti-chemokine mAb for IBD and other immune-mediated illnesses.

Image Credit : Unsplash

Takeda Pharmaceutical Company Limited is a partner in the company's diagnostics development and partnership; Dr.

Image Credit : Unsplash

Agreements between Millennium Pharmaceuticals, Inc. and Falk Pharma GmbH on the one hand, and Cedars-Sinai Medical Center and Falk Pharma GmbH on the other, represent a strategic partnership.

Image Credit : Unsplash

Prior to October 2019, the company went under the name Precision IBD, Inc. However, in same month, it officially changed its name to Prometheus Biosciences, Inc.

Image Credit : Unsplash

San Diego, California is home to Prometheus Biosciences, Inc., which was founded that year.

Image Credit : Unsplash

Qcom Stock Price, Quote and News

Image Credit : Unsplash

Arrow